Patents by Inventor John Frederick Quinn

John Frederick Quinn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biaryl derivatives as bromodomain inhibitors
    Patent number: 9765039
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: September 19, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: David John Fairfax, Gregory Scott Martin, John Frederick Quinn, Bryan Cordell Duffy, Gregory Steven Wagner, Peter Ronald Young
  • NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20170216257
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: April 20, 2017
    Publication date: August 3, 2017
    Inventors: Shuang Liu, John Frederick QUINN, Bryan Cordell DUFFY, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, He ZHAO, Michael ELLIS, Gregory Steven WAGNER, Peter Ronald YOUNG
  • NOVEL BICYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20170216301
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: April 12, 2017
    Publication date: August 3, 2017
    Inventors: John Frederick QUINN, Bryan Cordell DUFFY, Shuang LIU, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, Gregory Steven WAGNER, Peter Ronald YOUNG
  • NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20170182029
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: March 15, 2017
    Publication date: June 29, 2017
    Inventors: Shuang LIU, John Frederick QUINN, Bryan Cordell DUFFY, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, He ZHAO, Michael ELLIS, Gregory Steven WAGNER, Peter Ronald YOUNG
  • Substituted bicyclic compounds as bromodomain inhibitors
    Patent number: 9662311
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: May 30, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • Bicyclic bromodomain inhibitors
    Patent number: 9663520
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: May 30, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: John Frederick Quinn, Bryan Cordell Duffy, Shuang Liu, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, Gregory Steven Wagner, Peter Ronald Young
  • NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20170143731
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: February 3, 2017
    Publication date: May 25, 2017
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • Substituted bicyclic compounds as bromodomain inhibitors
    Patent number: 9636328
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: May 2, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • Heterocyclic compounds as bromodomain inhibitors
    Patent number: 9598367
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: March 21, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS
    Publication number: 20160193218
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: July 30, 2014
    Publication date: July 7, 2016
    Inventors: John Frederick QUINN, Vladimir KHLEBNIKOV
  • NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20160184273
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: June 20, 2014
    Publication date: June 30, 2016
    Applicant: ZENITH EPIGENETICS CORP.
    Inventors: Shuang LIU, John Frederick QUINN, Bryan Cordell DUFFY, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, He ZHAO, Michael ELLIS, Gregory Steven WAGNER, Peter Ronald YOUNG
  • NOVEL BICYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20160159801
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: December 21, 2015
    Publication date: June 9, 2016
    Inventors: John Frederick QUINN, Bryan Cordell DUFFY, Shuang LIU, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, Gregory Steven WAGNER, Peter Ronald YOUNG
  • NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20160145248
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: June 20, 2014
    Publication date: May 26, 2016
    Inventors: Shuang LIU, John Frederick QUINN, Bryan Cordell DUFFY, Ruifang WANG, May Xiacwu JIANG, Gregory Scott MARTIN, He ZHAO, Michael ELLIS, Gregory Steven WAGNER, Peter Ronald YOUNG
  • Novel Heterocyclic Compounds as Bromodomain Inhibitors
    Publication number: 20160130228
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: January 15, 2016
    Publication date: May 12, 2016
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • Cyclic amines as bromodomain inhibitors
    Patent number: 9278940
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: March 8, 2016
    Assignee: Zenith Epigenetics Corp.
    Inventors: David John Fairfax, Bryan Cordell Duffy, Gregory Scott Martin, John Frederick Quinn, Shuang Liu, Gregory Steven Wagner, Peter Ronald Young
  • Heterocyclic compounds as bromodomain inhibitors
    Patent number: 9271978
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 1, 2016
    Assignee: Zenith Epigenetics Corp.
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • CYCLIC AMINES AS BROMODOMAIN INHIBITORS
    Publication number: 20150344442
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: June 3, 2015
    Publication date: December 3, 2015
    Applicant: Zenith Epigenetics Corp.
    Inventors: David John Fairfax, Bryan Cordell Duffy, Gregory Scott Martin, John Frederick Quinn, Shuang Liu, Gregory Steven Wagner, Peter Ronald Young
  • Cyclic amines as bromodomain inhibitors
    Patent number: 9073878
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 7, 2015
    Assignee: Zenith Epigenetics Corp.
    Inventors: David John Fairfax, Bryan Cordell Duffy, Gregory Scott Martin, John Frederick Quinn, Shuang Liu, Gregory Steven Wagner, Peter Ronald Young
  • Novel Heterocyclic Compounds as Bromodomain Inhibitors
    Publication number: 20140179648
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: December 19, 2013
    Publication date: June 26, 2014
    Applicant: RVX Therapeutics Inc.
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • CYCLIC AMINES AS BROMODOMAIN INHIBITORS
    Publication number: 20140142102
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: November 20, 2013
    Publication date: May 22, 2014
    Applicant: RVX Therapeutics Inc.
    Inventors: David John Fairfax, Bryan Cordell Duffy, Gregory Scott Martin, John Frederick Quinn, Shuang Liu, Gregory Steven Wagner, Peter Ronald Young